Skip to Content
chevron-left chevron-right chevron-up chevron-right chevron-left arrow-back star phone quote checkbox-checked search wrench info shield play connection mobile coin-dollar spoon-knife ticket pushpin location gift fire feed bubbles home heart calendar price-tag credit-card clock envelop facebook instagram twitter youtube pinterest yelp google reddit linkedin envelope bbb pinterest homeadvisor angies

Invest in Robot Surgery

Robot Surgery is the umbrella term for using robot-assisted systems for surgeries.

Controlled by a surgeon via a computer, robotic surgical systems help surgeons with efficiency during the procedure. Robotic surgery systems are extremely precise, having the capability of creating incisions only millimeters in length and completing entire surgical procedures from incision to the stitching of the wound.

Benefits of using a robot-assisted surgical system include increased accuracy and precision during the surgical procedure in addition to causing less skin trauma, quicker recovery time, and decreases in both pain and risk of infection for the patient.

Minimally Invasive Surgery

Currently the most popular use case for robot surgical systems is for minimally invasive surgery, surgery that utilizes tiny incisions opposed to the larger wounds created in open surgical operations. Robot surgical platforms have historically been used for minimally invasive surgical procedures including urological, general laparoscopic, gynecological, thoracic, and some types of heart surgery. With the advancement in technology, these indications have now expanded to include surgeries for cancer, orthopedic, colectomies, splenectomies, and many others. In addition to the increasing indications, health professionals, along with patients, have warmed up to the concept of robot-assisted surgery over the last two decades.

The pioneer of robot surgery is Intuitive Surgical (NASD: ISRG) which began trading publicly in the early 2000’s. For the last 20 years, Intuitive Surgical has maintained dominance in the industry with their flagship product, the da Vinci surgical system, which currently has over 4,500 units in operation worldwide costing anywhere between $500,000 and $2.5 million per system. Due to a lack of real competition, Intuitive has been able to maintain both a powerful footprint and a de facto monopoly on the robot surgery market. However, new market entrants are challenging Intuitive for share in this fast-growing industry.

Major Developments

  • In 2013, Stryker (NYSE: SYK) acquired robotic surgery company Mako Surgical for $1.6 billion. The purchase price of $30 a share represented a large premium of 85% to the prior days closing price of $16. Stryker, one of the largest medical device makers on the planet, made the deal in order to further penetrate the robot surgery space as Mako’s surgical system assists doctors in the orthopedic implantation process.
  • Medtronic PLC (NYSE: MDT) acquired robot surgery firm Mazor Robotics in the fall of 2018 for a price tag of $1.7 billion
  • Johnson & Johnson (NYSE: JNJ) has made moves in the space as well. The pharma giant partnered up with Verily, Google’s life sciences venture arm, to create robot surgery company Verb Surgical (Johnson & Johnson now maintains sole control) and in the winter of 2018, Johnson & Johnson acquired French robot surgery company, Orthotaxy
  • In 2016, Medical device maker Zimmer Biomet (NYSE: ZBH) bought French company Medtech SA for their ROSA robotic device, which is used in neurological and spine procedures

The Future

Robots are being touted for their ability to both eliminate human error and assist in increasing job performance. With the amount of indications and medical device approvals expanding for these robot surgical platforms, health professionals will only find their jobs easier.

According to Thompson Reuters, the robot surgery market will register a CAGR of 21% through 2023 reaching a market value of $12 billion.

In the coming years, robot surgery will advance from performing minimally invasive procedures to carrying out more complex surgeries. Advancements in the field of robotics will only increase the value of robots in the surgical process. New systems will be built with extensive automation capabilities, the adoption of 5G wireless technology will allow doctors to assist colleagues with performing surgeries remotely, and expanding indications will make robot surgery systems even more valuable and ubiquitous.

Robot Surgery Stocks

Industry: Medical Instruments & Supplies

Sector: Healthcare

Website: http://www.intuitive.com

Description: Intuitive Surgical, Inc., together with its subsidiaries, designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company’s da Vinci Surgical System include surgeon’s consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; and EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.

Fundamentals
Market cap$91.04B
P/E ratio87.20
Earnings per share$8.82
Return on equity11.83%
Profit margin24.33%
Total revenue$4.36B
Debt / Equity0.82
Price / Book9.30
52 week high$826.81
52 week low$488.00
Shares outstanding$118.38M
Previous close$761.02
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Medical Devices

Sector: Healthcare

Website: http://www.transenterix.com

Description: TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company’s products include Senhance System, a multi-port robotic surgery system that allows multiple robotic arms to control instruments and a camera; and SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. It offers its products directly and through distributors in Europe, the United States, Japan, Taiwan, and other select countries. The company was founded in 2006 and is based in Morrisville, North Carolina.

Fundamentals
Market cap$916.88M
P/E ratio
Earnings per share$
Return on equity0.00%
Profit margin0.00%
Total revenue$0.00
Debt / Equity
Price / Book
52 week high$6.95
52 week low$0.28
Shares outstanding$0.00
Previous close$4.54
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Drug ManufacturersGeneral

Sector: Healthcare

Website:http://www.jnj.com

Description: Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women’s health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Fundamentals
Market cap$430.18B
P/E ratio29.66
Earnings per share$5.51
Return on equity23.97%
Profit margin17.82%
Total revenue$82.58B
Debt / Equity57.47
Price / Book6.80
52 week high$173.65
52 week low$133.65
Shares outstanding$2.63B
Previous close$163.61
Dividend Analysis
Dividend yield2.47%
Payout ratio72.23%
Trailing Annual Dividend Rate$3.98
Five Year Avg Dividend Yield2.62%
Ex-Dividend dateFebruary 21, 2021 6:00 PM

Industry: Medical Devices

Sector: Healthcare

Website: http://www.medtronic.com

Description: Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; electrosurgical hardware and instruments, and mesh fixation devices; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; colorectal surgeons; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Fundamentals
Market cap$163.10B
P/E ratio53.56
Earnings per share$2.26
Return on equity5.97%
Profit margin10.97%
Total revenue$27.93B
Debt / Equity59.54
Price / Book3.21
52 week high$122.05
52 week low$87.68
Shares outstanding$1.35B
Previous close$120.63
Dividend Analysis
Dividend yield1.92%
Payout ratio107.04%
Trailing Annual Dividend Rate$2.28
Five Year Avg Dividend Yield2.08%
Ex-Dividend dateMarch 24, 2021 7:00 PM

Industry: Medical Devices

Sector: Healthcare

Website: http://www.stryker.com

Description: Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Fundamentals
Market cap$93.94B
P/E ratio59.43
Earnings per share$4.20
Return on equity12.35%
Profit margin11.14%
Total revenue$14.35B
Debt / Equity110.25
Price / Book7.18
52 week high$250.05
52 week low$168.49
Shares outstanding$375.79M
Previous close$247.44
Dividend Analysis
Dividend yield1.02%
Payout ratio56.07%
Trailing Annual Dividend Rate$2.36
Five Year Avg Dividend Yield1.12%
Ex-Dividend dateMarch 29, 2021 7:00 PM

Industry: Medical Devices

Sector: Healthcare

Website: http://www.accuray.com

Description: Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

Fundamentals
Market cap$465.42M
P/E ratio62.63
Earnings per share$0.08
Return on equity11.43%
Profit margin2.03%
Total revenue$377.32M
Debt / Equity270.21
Price / Book5.99
52 week high$6.02
52 week low$1.68
Shares outstanding$92.90M
Previous close$4.95
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Medical Devices

Sector: Healthcare

Website:http://www.smith-nephew.com

Description: Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Fundamentals
Market cap$17.06B
P/E ratio37.55
Earnings per share$1.02
Return on equity8.60%
Profit margin9.83%
Total revenue$4.56B
Debt / Equity69.90
Price / Book3.19
52 week high$46.10
52 week low$34.29
Shares outstanding$439.48M
Previous close$37.86
Dividend Analysis
Dividend yield1.97%
Payout ratio73.24%
Trailing Annual Dividend Rate$0.38
Five Year Avg Dividend Yield1.83%
Ex-Dividend dateApril 4, 2021 7:00 PM

Industry: Medical Devices

Sector: Healthcare

Website: http://www.zimmerbiomet.com

Description: Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Fundamentals
Market cap$34.37B
P/E ratio
Earnings per share$ -0.67
Return on equity-1.12%
Profit margin-1.98%
Total revenue$7.02B
Debt / Equity69.70
Price / Book2.81
52 week high$170.05
52 week low$104.14
Shares outstanding$208.32M
Previous close$162.75
Dividend Analysis
Dividend yield0.59%
Payout ratio0.00%
Trailing Annual Dividend Rate$0.96
Five Year Avg Dividend Yield0.77%
Ex-Dividend dateMarch 25, 2021 7:00 PM

Load More

Contact Us For Opportunities in the Private Market